Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY.
Company profile
Ticker
NTRP
Exchange
Website
CEO
Charles Ryan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BlueFlash Communications, Inc.
SEC CIK
Corporate docs
NTRP stock data
Latest filings (excl ownership)
8-K
Neurotrope and Metuchen Pharmaceuticals Announce Completion of
7 Dec 20
25-NSE
Exchange delisting
2 Dec 20
8-K
Submission of Matters to a Vote of Security Holders
25 Nov 20
DEFA14A
Additional proxy soliciting materials
24 Nov 20
8-K
Other Events
24 Nov 20
DEFA14A
Additional proxy soliciting materials
20 Nov 20
8-K
Neurotrope, Inc. Approves Spin-Off of Neurotrope
20 Nov 20
10-Q
2020 Q3
Quarterly report
9 Nov 20
DEFM14A
Proxy related to merger
2 Nov 20
425
Business combination disclosure
30 Sep 20
Latest ownership filings
Financial summary
Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 27.00 mm | 27.00 mm | 27.00 mm | 27.00 mm | 27.00 mm | 27.00 mm |
Cash burn (monthly) | 1.08 mm | (no burn) | 1.42 mm | (no burn) | 1.08 mm | 801.86 k |
Cash used (since last report) | 46.43 mm | n/a | 60.97 mm | n/a | 46.43 mm | 34.35 mm |
Cash remaining | -19.43 mm | n/a | -33.97 mm | n/a | -19.43 mm | -7.35 mm |
Runway (months of cash) | -17.9 | n/a | -23.9 | n/a | -17.9 | -9.2 |
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|